The excitement round an imminent Covid-19 vaccine has raised hopes of a means again to normalcy for the billions affected by the pandemic around the globe, stated Kiran Mazumdar-Shaw, chairperson and managing director of Bengaluru-based Biocon Ltd.
Mazumdar-Shaw is hopeful that the vaccine will likely be in India by June, however added that delivering it to all Indians comes with its personal challenges. Biocon, which introduced its September quarter earnings on Friday, noticed its web revenue fall to Rs 169 crore from Rs 216 crore within the year-ago quarter. In an interview, she shared her views on the vaccine and its challenges. Edited excerpts:
When can we count on a Covid-19 vaccine in India?
My expectation is that the primary mRNA vaccines will likely be permitted by the top of the 12 months. However they don’t seem to be going to be obtainable in India as a result of they require a -80 diploma chilly chain and that’s not one thing which we are able to deal with right here. I count on that by January, a number of the different vaccines could possibly be permitted like AstraZeneca’s, or one in all our personal Indian vaccines, just like the one by Bharat Biotech. If we end the scientific trials within the subsequent 2-3 months, even these could also be permitted by January-February. So, I might count on that in Q1 2021-22 we must always have vaccines obtainable in India.
What are the challenges you foresee in vaccine distribution right here?
This scale of grownup vaccination has by no means been performed earlier than. Polio vaccine was performed over a few years. The polio vaccine may be given by ASHA staff and others, however Covid vaccines will likely be intramuscular injections, and you will have nurses, docs, MBBS college students to ship the vaccine. Aside from human assets, we have to get infrastructure for chilly chains to be arrange correctly.
Learn the complete interview on livemint.com